Entera Bio Ltd.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$275M
Investors
53
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Entera Bio Ltd. is a Israel corporation that filed a Form D with the SEC on August 12, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Entera Bio Ltd. reported $274,999,976 sold from 53 investors of a $274,999,976 total offering as of the Form D filed August 12, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Leerink Partners LLC, associated with None; Evercore Group L.L.C. (CRD 000042405), associated with None; Guggenheim Securities, LLC (CRD 000040638), associated with None; Cantor Fitzgerald & Co. (CRD 000000134), associated with None and 2 others as recipients of sales compensation. The issuer's address of record is Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, 9112002.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
3
latest Aug 12, 2026
Critical / warning
0 / 2
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
lapsed, closed
Latest event New filer · Aug 12, 2026
SEC.govInvestor
- 3 filing events with values and deltas, latest 2026-08-12, and alerts on the next one
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-08-12: 2 related persons added and 6 removed against the filing of 2024-01-02; 7 now listed. The names are in the Terminal feed.
Miranda Toledano
Executive Officer, Director · Jerusalem, L3
Chief Executive Officer
Haya Taitel
Director · Jerusalem, L3
Yonatan Malca
Director · Jerusalem, L3
Dana Yaacov-Garbeli
Executive Officer · Jerusalem, L3
Chief Financial Officer
Geno J. Germano
Director · Jerusalem, L3
Chairman of the Board
Sean Ellis
Director · Jerusalem, L3
Steven D. Rubin
Director · Jerusalem, L3
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Leerink Partners LLC
Associated broker-dealer: None · Boston, MA
Evercore Group L.L.C.CRD 000042405 on BrokerCheck
Associated broker-dealer: None · New York, NY
Guggenheim Securities, LLCCRD 000040638 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Cantor Fitzgerald & Co.CRD 000000134 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
LifeSci Capital, LLCCRD 000168404 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Canaccord Genuity LLCCRD 000001020 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Questions About Entera Bio Ltd.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Entera Bio Ltd.?
Entera Bio Ltd. is a Israel corporation that filed a Form D with the SEC on August 12, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is Entera Bio Ltd. legit?
AltStreet does not rate legitimacy; it reports the public record. Entera Bio Ltd. filed a Form D with the SEC on August 12, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $274,999,976 sold to 53 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Entera Bio Ltd. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Entera Bio Ltd. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Entera Bio Ltd. raised?
Entera Bio Ltd. reported $274,999,976 sold from 53 investors of a $274,999,976 total offering as of the Form D filed August 12, 2026.
Who can invest in Entera Bio Ltd.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Entera Bio Ltd.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Entera Bio Ltd. and how are they paid?
The Form D names Leerink Partners LLC, associated with None; Evercore Group L.L.C. (CRD 000042405), associated with None; Guggenheim Securities, LLC (CRD 000040638), associated with None; Cantor Fitzgerald & Co. (CRD 000000134), associated with None and 2 others as recipients of sales compensation.
Who is behind Entera Bio Ltd.?
The Form D lists 7 related persons: Miranda Toledano, executive officer, director (Chief Executive Officer); Haya Taitel, director; Yonatan Malca, director; Dana Yaacov-Garbeli, executive officer (Chief Financial Officer); Geno J. Germano, director (Chairman of the Board); Sean Ellis, director; Steven D. Rubin, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Entera Bio Ltd. located?
The issuer's address on its SEC filings is Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, 9112002. Its phone number of record is 972-2-532-7151. It is organized under the laws of Israel.
How long is the Entera Bio Ltd. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Entera Bio Ltd.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
